Related Experiment Video
Updated: Feb 9, 2026

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System
Published on: July 30, 2018
The preventive and therapeutic implication for renal fibrosis by targetting TGF-β/Smad3 signaling
Yun Zhang1,2, Xiao-Ming Meng2,3, Xiao-Ru Huang2
1Department of Dermatology, Foshan Hospital of Traditional Chinese Medicine, Foshan, China.
Abstract:
It is well established that Smad3 is a key downstream effector of transforming growth factor-β (TGF-β) signaling in tissue fibrogenesis. We reported here that targetting Smad3 specifically with a Smad3 inhibitor SIS3 is able to prevent or halt the progression of renal fibrosis in a mouse model of unilateral ureteral obstructive nephropathy (UUO). We found that preventive treatment with SIS3 at the time of disease induction largely suppressed progressive renal fibrosis by inhibiting α-smooth muscle actin (α-SMA) + myofibroblast accumulation and extracellular matrix (collagen I (Col.I) and fibronectin (FN)) production. Importantly, we also found that treatment with SIS3 on established mouse model of UUO from day 4 after UUO nephropathy halted the progression of renal fibrosis. Mechanistically, the preventive and therapeutic effects of SIS3 on renal fibrosis were associated with the inactivation of Smad3 signaling and inhibition of TGF-β1 expression in the UUO kidney. In conclusion, results from the present study suggest that targetting Smad3 may be a specific and effective therapy for renal fibrosis.
Insights
Targeting Smad3 with the inhibitor SIS3 effectively prevents and halts renal fibrosis progression in a mouse model. This therapeutic approach inhibits key fibrotic markers and TGF-β1 signaling, suggesting Smad3 as a viable target for kidney fibrosis treatment.
Area of Science:
- Nephrology
- Molecular Biology
- Pharmacology
Background:
- Transforming growth factor-β (TGF-β) signaling is crucial in tissue fibrogenesis.
- Smad3 acts as a key downstream mediator in TGF-β-induced fibrotic processes.
- Renal fibrosis is a significant pathological condition characterized by excessive extracellular matrix deposition.
Purpose of the Study:
- To investigate the efficacy of Smad3 inhibition using SIS3 in preventing and treating renal fibrosis.
- To elucidate the molecular mechanisms underlying the antifibrotic effects of SIS3 in a mouse model.
Main Methods:
- Utilized a unilateral ureteral obstructive nephropathy (UUO) mouse model to induce renal fibrosis.
- Administered SIS3 preventively at disease induction and therapeutically after disease establishment (day 4).
- Assessed renal fibrosis by measuring α-smooth muscle actin (α-SMA) positive myofibroblasts and extracellular matrix components (collagen I, fibronectin).
- Analyzed Smad3 signaling pathway activation and TGF-β1 expression in kidney tissues.
Main Results:
- Preventive SIS3 treatment significantly suppressed renal fibrosis by inhibiting myofibroblast accumulation and extracellular matrix production.
- Therapeutic SIS3 treatment initiated on day 4 post-UUO halted the progression of established renal fibrosis.
- Both preventive and therapeutic effects were correlated with Smad3 pathway inactivation and reduced TGF-β1 expression in the affected kidneys.
Conclusions:
- Targeting Smad3 with SIS3 demonstrates significant potential in both preventing and treating renal fibrosis.
- Smad3 inhibition offers a specific and effective therapeutic strategy for managing kidney fibrotic diseases.
- The findings support Smad3 as a key molecular target for developing novel antifibrotic therapies.
Related Concept Videos
TGF - β Signaling Pathway
Endocrine Signaling
Cancer Prevention
Some...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
What is Cell Signaling?
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...

